Italian World Cup winner and Guangzhou Evergrande gaffer Fabio Cannavaro (Photo | APF) 
Sports News

Guangzhou Evergrande to build two more 80,000-seat stadiums in China

CSL clubs are building or renovating a clutch of stadiums with the country set to host the newly expanded 2021 FIFA Club World Cup and AFC Asian Cup in 2023.

From our online archive

SHANGHAI: The wealthy owners of Chinese champions Guangzhou Evergrande will build two stadiums with capacities of 80,000 each, in addition to the club's new 100,000-seat home.

Chinese Super League (CSL) clubs are building or renovating a clutch of stadiums with the country set to host the newly expanded 2021 FIFA Club World Cup and AFC Asian Cup in 2023.

But the rush on new arenas will also heighten speculation that China is gearing up for a bid to host the World Cup, possibly in 2030.

Evergrande Group, a major property developer, has asked fans to pick their favourite designs for two more new stadiums.

"Evergrande plans to build two additional 80,000-seat football fields and invites everyone to recommend two of the six preliminary plans," Guangzhou Evergrande's owners said on social media.

The statement did not give any further information such as where in China or when the stadiums would be built.

CSL champions Guangzhou Evergrande, coached by Italian World Cup winner Fabio Cannavaro, began work Thursday on their eye-catching new home.

Costing 12 billion yuan ($1.7 billion), it will be bigger than Barcelona's famous Camp Nou and is scheduled for completion by the end of 2022.

Evergrande Group's founder is the billionaire Xu Jiayin, one of the richest men in China.

Why the additional declaration linked to Form 6 is facing a legal challenge

SP-Congress alliance faces fresh strain as Akhilesh skips INDIA bloc meet over UP seat-sharing talks

Rahul Gandhi tells CWC to continue 'resistance' against 'match-fixing' of polls through EVM, voters list

Assam Rifles jawan killed in militant attack in Arunachal; security forces intensify ops to arrest killers

SC slams medicine pricing, calls cancer drug’s 10-fold MRP markup ‘carnage’